We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Taysha Gene Therapies Inc | NASDAQ:TSHA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.34 | 2.35 | 2.55 | 15 | 09:58:30 |
From May 2023 to May 2024
By Dean Seal
Taysha Gene Therapies said regulators have granted fast-track designation for TSHA-102, a gene transfer therapy in clinical evaluation for the neurodevelopmental disorder Rett Syndrome.
The Dallas-based clinical-stage company said the special status from the U.S. Food and Drug Administration has been granted after encouraging initial data from the first adult patient in Canada dosed with TSHA-102. A second patient is set to be dosed in the current quarter.
The FDA's fast-track designation facilitates the development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
TSHA-102 also has received orphan-drug and rare-pediatric-disease designations from the FDA, as well as orphan-drug designation from the European Commission.
Shares climbed 8% to $2.40 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 24, 2023 08:37 ET (12:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Taysha Gene Therapies Chart |
1 Month Taysha Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
